Anthracyclines in Early Breast Cancer: The Long Goodbye | Journal of Clinical Oncology
For more than 50 years, through successive iterations of regimens incorporating alkylating agents, anthracyclines, and taxanes, adjuvant cytotoxic chemotherapy has improved the prognosis of patients with early breast cancer, reducing recurrence and cancer-related death. 1, 2 Remarkable progress in supportive care—especially antiemetics and growth factor support—has made treatment feasible and tolerable for a greater percentage of patients, although longer-term risks remain, including neuropathy, fatigue,
